Table 1 The basic characteristic of included studies
Study | Region | Outcomes | Treatment | Sample size (female/male) | Age (years) | K–L grade | Follow-up duration | Funder | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | Intervention | Control | ||||||
Kuptniratsaikul V 2009 [56] | Thailand | VAS, AEs | CL extract | Ibuprofen | 52 (41/11) | 55 (45/10) | 61.4 ± 8.7 | 60.0 ± 8.4 | - | 6 weeks | Research department |
Kuptniratsaikul V 2014 [57] | Thailand | WOMAC, AEs | CL extract | Ibuprofen | 171 (157/14) | 160 (139/21) | 60.30 ± 6.8 | 60.9 ± 6.9 | 1–4 | 4 weeks | Research department |
Nakagawa Y 2014 [61] | Japan | VAS, AEs, Inflammatory Biomarkers | Nano-curcumin (Theracurmin®) | Placebo | 18 (14/4) | 23 (18/5) | 66.10 ± 7.2 | 71.9 ± 5.3 | 2–3 | 8 weeks | Private corporation |
Panahi Y 2014 [62], Panahi Y 2015 [63], Rahimnia AR 2015 [64] | Iran | VAS, WOMAC, AEs, Inflammatory Biomarkers | Curcuminoids (C3 complex®) | Placebo | 19 (14/5) | 21 (17/4) | 57.32 ± 8.78 | 57.57 ± 9.05 | - | 6 weeks | Research department |
Srivastava S 2016 [65] | India | VAS, WOMAC, AEs, Inflammatory Biomarkers | CL extract (Haridra®) | Placebo | 78 (53/25) | 82 (50/32) | 50.23 ± 8.08 | 50.27 ± 8.63 | 1–4 | 4 months | Research department |
Haroyan A 2018 [66] | Armenia | WOAMC, AEs, laboratory indicators | Curcuminoids (CuraMed®) | Placebo | 66 (60/6) | 68 (65/3) | 54.65 ± 8.84 | 56.04 ± 8.55 | 1–3 | 12 weeks | Private corporation |
Panda SK 2018 [67] | India | VAS, WOMAC, AEs, Inflammatory Biomarkers | Curcuminoids (Curene®) | Placebo | 25 | 25 | 55.2 ± 8.58 | 53.12 ± 8.25 | 2–3 | 2 months | Private corporation |
Gupte PA 2019 [58] | India | VAS, AEs, Inflammatory Biomarkers | Curcumin (Longvida®) | Ibuprofen | 17 (11/6) | 25 (23/2) | 57 ± 7.5 | 54.0 ± 8.0 | 1–4 | 3 months | Private corporation |
Herotin Y 2019 [68] | Belgium | VAS, AEs, Inflammatory Biomarkers | Curcumin (FLEXOFYTOL®) | Placebo | 47 (40/7) 49 (39/15) | 45 (34/11) | 61.4 ± 7.49 60.9 ± 9.78 | 63.3 ± 7.69 | 2–4 | 6 months | Private corporation |
Shep D 2019 [59] | India | VAS, AEs, Inflammatory Biomarkers | Curcuminoids (BCM-95®) | Diclofenac | 70 (25/45) | 69 (21/48) | 53.09 ± 4.17 | 52.14 ± 3.76 | - | 4 weeks | Not applicable |
Wang Z 2020 [69] | Australia | VAS, WOMAC, AEs, MRI | CL extract (Turmacin Plus) | Placebo | 36 (18/18) | 34 (21/13) | 61.3 ± 8.5 | 62.4 ± 8.8 | - | 12 weeks | Private corporation |
Atabaki M 2020 [70] | Iran | VAS, AEs, Inflammatory Biomarkers | Nano-curcumin (SinaCurcumin®) | Placebo | 15 (15/0) | 15 (15/0) | 49.13 ± 5.81 | 48.26 ± 5.11 | 2–3 | 3 months | Research department |
Hashemzadeh K 2020 [71] | Iran | WOMAC, AEs, Inflammatory Biomarkers | Nano-curcumin (SinaCurcumin®) | Placebo | 36 (29/7) | 35 (31/4) | 54.11 ± 5.8 | 56.54 ± 5.77 | 2–3 | 6 weeks | Research department |
Singhal S 2021 [60] | India | WOAMC, AEs | Curcuminoids (BCM-95®) | Paracetamol | 73 (53/20) | 71 (54/17) | 53.1 ± 10.9 | 50.8 ± 9.9 | 2–3 | 6 weeks | Not applicable |
Lopresti L 2022 [72] | Australia | VAS, AEs | Curcumin (Curcuge®) | Placebo | 51 (24/27) | 50 (26/24) | 59.6 ± 6.57 | 57.9 ± 6.22 | - | 8 weeks | Private corporation |